AGL.L
ANGLE plc [AGL.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AGL.L Stock Summary
In the News
AGL.L Financial details
Company Rating
-
Market Cap
32.56M
Income
-33.42M
Revenue
2.73M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
173
Optionable
No
Shortable
Yes
Earnings
15 Apr 2024
P/E
-2.88
Forward P/E
-
PEG
-0.31
P/S
60.72
P/B
1.56
P/C
-
P/FCF
-3.52
Quick Ratio
6.08
Current Ratio
7.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.13
EPS next Y
-
EPS next Q
-
EPS this Y
31.78%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
6.03%
Revenue last 5Y
8.95%
Revenue Q/Q
100%
EPS Q/Q
100.53%
-
-
-
-
SMA20
-9.28%
SMA50
-24.86%
SMA100
-53.5%
Inst Own
-
Inst Trans
-
ROA
-43%
ROE
-54%
ROC
-0.54%
Gross Margin
59%
Oper. Margin
-2325%
Profit Margin
-2083%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.067-37.4
52W High
-82.84%
52W Low
-29.44%
RSI
36.15
Rel Volume
0.24
Avg Volume
1.56M
Volume
370.18K
Perf Week
-12.41%
Perf Month
-15.33%
Perf Quarter
-42.27%
Perf Half Y
-42.27%
-
-
-
-
Beta
0.122
-
-
Volatility
0.16%, 0.54%
Prev Close
1.6%
Price
6.35
Change
3.08%
Company Profile
- Volume Average 1.56M
- Market Capitalization 32.56M
- Employee 173
- CEO Mr. Andrew David William Newland ACA, Meng
- Headquarters Guildford,GB
- IPO Date 2004-03-17
-
Website
https://angleplc.com 
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.
